Register for free to
view the full innovation profile.
Septest is a rapid, point-of-care test that detects critical infection markers in minutes, enabling early sepsis diagnosis and timely treatment to save lives.
About
Septest Limited is a medtech company revolutionizing sepsis diagnosis with a rapid, accessible, point-of-care test. Sepsis, a life-threatening condition impacting 49 million people annually and causing 11 million deaths, progresses rapidly, with each hour of delayed treatment reducing survival chances by 8-10%. Yet, most diagnostics are slow and lab-based, with results often delayed by hours to days, resulting in critical treatment delays. Septest’s innovative test detects key infection and inflammation markers within minutes, empowering clinicians to make timely, life-saving treatment decisions. Designed for emergency departments, primary care, and remote settings, our test enables healthcare providers to act quickly, reducing preventable deaths, ICU admissions, and healthcare costs.
Key Benefits
Rapid Diagnosis: Provides sepsis detection within minutes, empowering healthcare providers to make timely, life-saving treatment decisions that improve patient outcomes.
Accessible Point-of-Care Solution: Designed for use across various healthcare settings—including emergency departments, primary care, and remote clinics—Septest ensures critical diagnostics are available wherever sepsis cases may arise.
Comprehensive Infection Detection: Identifies the type and severity of infections, enabling more accurate and targeted treatment, reducing unnecessary antibiotic use, and helping curb antimicrobial resistance (AMR).
Cost Savings: Early sepsis detection can significantly reduce hospital stays, ICU admissions, and related healthcare costs, addressing a global healthcare expenditure burden estimated at billions annually.
Versatile Applications: Beyond traditional healthcare settings, Septest offers value for military, trauma, and veterinary applications, broadening its impact across multiple markets and needs.
Applications
Our primary target market includes healthcare providers across emergency departments, primary care, and community health settings where early sepsis detection is critical. Secondary markets include military, trauma care, and global health organizations seeking rapid diagnostics in resource-limited settings. Additionally, veterinary diagnostics represent an emerging segment, leveraging our technology to address infection detection needs across animal health.